Stem Pharm, Inc

[Not Yet Scheduled]
Stem Pharm is pioneering advanced human neural organoids for CNS disease modeling, drug discovery, and toxicology. Initially, the company is targeting applications to neurodegeneration, brain tumors, and developmental neurotoxicity. Stem Pharm’s neural organoids are enabled by the company’s synthetic hydrogel platform, that consists of a portfolio of engineered biomaterials with application that offer a synthetic alternative to Matrigel for high-value applications.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Wisconsin
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
Neural organoid and associated biomaterials
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Stem Pharm, Inc.